Satyanarayana Chava – CEO, Laurus Labs, India
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
Laurus Labs Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in India and internationally. It operates through Laurus Generics APIs, Laurus Generics Finished Dosage Forms (FDF), Laurus Synthesis, and Laurus Ingredients divisions.
The Laurus Generics APIs division develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), Hepatitis C, cardiovascular, antidiabetic, anti-asthmatic, gastroenterology, oncology, and ophthalmic therapeutic areas. The Laurus Generics Finished Dosage Forms division develops and manufactures oral solid formulations, such as ARVs, anti-diabetic, cardiovascular, and proton pump inhibitors.
The Laurus Synthesis division provides contract development and manufacturing services for pharmaceutical companies. The Laurus Ingredients division manufactures and sells speciality ingredients for use in the nutraceutical/dietary supplements and cosmeceutical products. In addition, it offers chemistry, IP development, business support, and related services to the pharmaceutical community. The company was incorporated in 2005 and is based in Hyderabad, India. Laurus Labs Limited is a subsidiary of Aptuit LLC.
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
KV Subramaniam, president of Reliance Life Sciences, a research-driven medical biotech with a fully integrated value chain that covers everything from research to manufacturing, comments on the firm’s unique positioning…
Suresh Pattathil wears two hats within India’s vast pharma ecosystem. Not only is he responsible for managing AbbVie India as its Managing Director and GM, he also advocates for broader…
In the latest blow to Indian pharma’s reputation, the European Medicines Agency (EMA) has recommended the suspension of marketing authorisations for a large number of generics tested by Indian CRO…
Director of the oldest and largest cancer centre in India, the Tata Memorial Hospital, C S Pramesh also heads up the National Cancer Grid (NCG), a nationwide network of over…
Over the course of his 40-year career, oncologist Dr Ramakant Deshpande has taken an active role in the evolution of cancer care in India and in 2017 he became the…
Ayushman Bharat, launched in 2018, is a monumental scheme addressing the lack of healthcare accessibility and affordability for over 500 million people in India. Dr Indu Bhushan, Ayushman Bharat’s inaugural…
India’s chemical industry is of vital importance to several industries, including pharmaceuticals, and exported USD 30.18 billion worth of products in 2022-23. Chemexcil’s Raghuveer Kini discusses his industry’s key role…
Pratima Reddy, GM at Merck Healthcare India reviews the importance of Merck’s Indian affiliate, discusses the recent reforms that have contributed both to improving patient access and to fostering foreign…
The Indian pharma industry has demonstrated spectacular growth based on its strength as a global generics manufacturer. Yet Indian pharma is not merely resting on its laurels. After shining through…
Sandeep Verma shares his journey of establishing Bayer’s consumer healthcare division in India and reflects on the challenges faced during the division’s inception amidst the COVID-19 pandemic, emphasizing the importance…
India’s pharma industry has big dreams. At the recent Annual Summit of Organisation of Pharmaceutical Producers of India (OPPI) the nation’s policymakers, academicians, industry leaders, innovators, and scientists gathered to…
Peter DeYoung shares the significance of Indian giant Piramal Pharma’s recent demerger from its parent company and its current strategic focus on organic growth, brownfield expansions, and “complex hospital generics.”…
See our Cookie Privacy Policy Here
